Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Page 1of 3Novacyt S.A.("Novacyt", the "Company" or the “Group”)FULL YEAR TRADING ANDOPERATIONAL UPDATEParis, France and Camberley, UK –28 January 2020–Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited revenues for the year ended31 December 2019 and provides an operationalupdate.The Company will report its full year results in April 2020. Graham Mullis, Group CEO of Novacyt, commented:“I am encouraged that last year we completed the disposal of the two non-core businesses and also completed a major restructure of the balance sheet to providemuch needed working capital. Despite working capital constraints, which impacted most of 2019, we demonstrated significant levels of growth in key parts of the business andcontinue to see increasing demand for our products. I look forward to growing the business from a stronger financial position in 2020.”2019 Trading UpdateThe Company announces that year end revenues from continuing operations will be approximately €13.1m, a reduction of 5% (6% CER) on a consolidated basis compared to 2018.Excluding the Clinical Lab, which was sold in July2019, revenue reduced by 2%(3% CER).As previously announced, trading was impacted from the second quarter of 2019 onwards due to working capitalconstraints.Long manufacturing lead times meant that it was challenging to achieve any significant recovery in the last few weeks of 2019given that the financing was only completed in November 2019.With the lower trading, management now expect the full year EBITDA to be lower than theprior year.The Company has started 2020 with an order book significantly higher than at the same time last year. Lab21 Products had confirmed orders of €1.6mat the end of the year.Of these orders,€1.3mcould not be delivered due to working capital and supply chain issues and are expected to be fulfilled during the first halfof 2020.Since the announcement of a new term loan and cancellation of the convertible bond facility in November 2019, Novacyt has started to invest funds in the recovery of its supply chain.The Company expects that it will take most of the first half of 2020 to fully restore manufacturing output and stock to normal levels.Core reagent sales across the Group grew by 3% year-on-year, with Primer design delivering 8%higher reagent revenues. Primerdesign also achieved international revenue growth of 12% despite restrictedq16 instrument sales due to lack of stock. This strong international performance was largely offset by weaker sales in the smaller UK direct market(down 13%) following a restructuring of the commercial team in the second quarter of 2019.Microgen Bioproductssales, part of the Lab21 Products business were also strong despite the continued stock shortages,as demonstrated by the UK and Ireland direct sales increasingby13% and Middle East sales increasingby8% on the prior year. In April komt het jaarresultaat over 2019. Kind regards, Forecast
Operational update Development of new coronavirus test Primer design is pleased to report that it is in the final stages of developing a new molecular novel coronavirus (2019-nCoV) test as a direct response to the recent outbreak of the potentially deadly respiratory virus in China. The Company will make the test available as are search use only (RUO)test for use on Primer design’s proprietary genesig® Q16 and Q32 instruments, as well as a number of other real-time PCR instruments commonly used in testing laboratories.A number of Novacyt’s customers have already enquired about the availability of this test and orders have already been received.This virus is of major concern as it is from the same family of viruses as severe acute respiratory syndrome (SARS), which emerged in China in 2002 and killed nearly 800 people worldwide.Authorities have recently confirmed that the virus can be passed from person to person via airborne transmission sparking concerns over the level of contagion. The World Health Organisation (WHO)reported that,as of 22 January, countries including the US, Singapore, Australia, Japan, Thailand and Korea are reporting the presence of this infection.The virus is not currently considereda global health emergency as designated by the WHO but this may change as more data becomes available. The Primer design test is therefore well positioned to quickly assist affected countries.
UK –7February2020– Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,provides an update following the launch of its research use only (RUO) test for novel coronavirus(2019-nCoV),which has been developed by its subsidiary Primer design as a direct response to the recent outbreak of the respiratory virus in China.Since the World Health Organization declared the 2019-nCoV outbreak a global emergency on the 30January 2020, the Company has seen strong demand for its nCoV test,which was launched on 31 January 2020.To date, Primer design has received orders for 33,000testsandrequests for quotations for another 32,000tests from over 30 countries,witha high conversion rate from quotations to orders.The Directors believe the Company is well placed to support the growing global demand for nCoV testing.The Company is also pleased to announce it is planning to launch a CE-Mark approved nCoV test in the week commencing 17 February. This approval will mean the nCoV test can be usedfor clinical diagnostic testing, as well as expanding itsusewithin laboratories.The Directors believe that Primer design will be one of the first companies to market its test with CE-Markapproval.In addition, the Company has applied to the US Food and Drug Administration(FDA) for Emergency Use Approval (EUA) of its nCoV test.EUA approval would allow laboratories in the US to use the nCoV test for clinical diagnosis on a temporary basis. The Companyis working with the FDA in order to demonstrate the consistency and performance of the Primerdesign testforemergency use.The Company is also in discussions with various NHS hospitals and Public Health England regarding the nCoV test and it has already sold a limited number of tests to certain hospitals for their validation purposes.As previously announced, the Primer design nCoV testis designed to detect only the 2019 strain of the virus, which the Directors believe differentiates it from a number of current tests which are less specific and could, therefore, react to other related viruses, potentially giving rise to a false diagnosis. The Primer design test can generate a result in less than two hours meaning that all samples can be screened quickly,which could help stop the unnecessary spread of this virus.The test is also stable at ambient temperatures, which eliminates the need for cold chain shipping in tropical climates and therefore improves the efficiency of the test and reduces transport costs.Graham Mullis, Chief Executive Officer of Novacyt commented:“It is still early days in this public health emergency, however coronavirus has already been reported in 23 countries with more than28,000 reported infections.As one of the first companies to develop and launch a test to detect the 2019 strain of nCoV,we have received unprecedented interest in our test and anticipate demand continuing to grow.In addition, we look forward to launching ourCE-Mark approved nCoV test,which we believe provides laboratories with a fast and reliable nCoV test without the need to carry out their own validation.We continue to support our new and existing customers and are working with the various regulatory authorities to try to make ournCoV test available to as many countries and laboratories as possible to support clinicians in reducing the spread of the disease.” Kind regards, Forecast
World News February 9, 2020 / 12:55 PM / Updated 6 hours ago China allocates $10.26 billion to fight coronavirus 1 Min Read Medical workers in protective suits attend to novel coronavirus patients at the intensive care unit (ICU) of a designated hospital in Wuhan, Hubei province, China February 6, 2020. Picture taken February 6, 2020. China Daily via REUTERS BEIJING (Reuters) - China’s finance ministry said on Sunday all levels of government had allocated a total of 71.85 billion yuan ($10.26 billion) as of Saturday afternoon to fight coronavirus. The ministry will deploy the funds to ensure that members of public can afford diagnosis and treatment, it said in a statement on its website. The funds will also be used to ensure that efforts of every region to fight the virus are not hampered by financial constraints, it added.
Novacyt wordt nu ook door huisartsen in Nederland gebruikt. Kind regards, Forecast
Update on novel coronavirus test Paris, France and Camberley, UK – 7 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides an update following the launch of its research use only (RUO) test for novel coronavirus (2019-nCoV), which has been developed by its subsidiary Primerdesign as a direct response to the recent outbreak Voor meer, zie de site van Novacytnovacyt.com/news-and-events/
Novacyt S.A. ("Novacyt", the "Company" or the “Group”) FULL YEAR TRADING AND OPERATIONAL UPDATE Paris, France and Camberley, UK – 28 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited revenues for the year ended 31 December 2019 and provides an operational update. The Company will report its full year results in April 2020. Graham Mullis, Group CEO of Novacyt, commented: “I am encouraged that last year we completed the disposal of the two non-core businesses and also completed a major restructure of the balance sheet to provide much needed working capital. Despite working capital constraints, which impacted most of 2019, we demonstrated significant levels of growth in key parts of the business and continue to see increasing demand for our products. I look forward to growing the business from a stronger financial position in 2020.” Voor meer, zie link:novacyt.com/wp-content/uploads/2020/0...
Wat meer informatie uit de link:2019 Trading Update The Company announces that year end revenues from continuing operations will be approximately €13.1m, a reduction of 5% (6% CER) on a consolidated basis compared to 2018. Excluding the Clinical Lab, which was sold in July 2019, revenue reduced by 2% (3% CER). As previously announced, trading was impacted from the second quarter of 2019 onwards due to working capital constraints. Long manufacturing lead times meant that it was challenging to achieve any significant recovery in the last few weeks of 2019 given that the financing was only completed in November 2019. With the lower trading, management now expect the full year EBITDA to be lower than the prior year. The Company has started 2020 with an order book significantly higher than at the same time last year. Lab21 Products had confirmed orders of €1.6m at the end of the year. Of these orders, €1.3m could not be delivered due to working capital and supply chain issues and are expected to be fulfilled during the first half of 2020. Since the announcement of a new term loan and cancellation of the convertible bond facility in November 2019, Novacyt has started to invest funds in the recovery of its supply chain. The Company expects that it will take most of the first half of 2020 to fully restore manufacturing output and stock to normal levels. Core reagent sales across the Group grew by 3% year-on-year, with Primerdesign delivering 8% higher reagent revenues. Primerdesign also achieved international revenue growth of 12% despite restricted q16 instrument sales due to lack of stock. This strong international performance was largely offset by weaker sales in the smaller UK direct market (down 13%) following a restructuring of the commercial team in the second quarter of 2019. Microgen Bioproducts sales, part of the Lab21 Products business were also strong despite the continued stock shortages, as demonstrated by the UK and Ireland direct sales increasing by 13% and Middle East sales increasing by 8% on the prior year. Page 2 of 3 The discontinued NOVAprep® operation achieved sales of €1.3m, which are excluded from Group consolidated revenue and do not impact the growth metrics stated above. These sales were generated before the sale of the business in December 2019 and represent 37% growth compared to the prior year which helped the division deliver positive cash flow for the Group in 2020, with a significant net cash contribution of €0.7m in the second half of the year. At 31 December 2019, the Group held cash and cash equivalents of €1.8m (2018: €1.1m).
Operational update Development of new coronavirus test Primerdesign is pleased to report that it is in the final stages of developing a new molecular novel coronavirus (2019-nCoV) test as a direct response to the recent outbreak of the potentially deadly respiratory virus in China. The Company will make the test available as a research use only (RUO) test for use on Primerdesign’s proprietary genesig® Q16 and Q32 instruments, as well as a number of other real-time PCR instruments commonly used in testing laboratories. A number of Novacyt’s customers have already enquired about the availability of this test and orders have already been received. This virus is of major concern as it is from the same family of viruses as severe acute respiratory syndrome (SARS), which emerged in China in 2002 and killed nearly 800 people worldwide. Authorities have recently confirmed that the virus can be passed from person to person via airborne transmission sparking concerns over the level of contagion. The World Health Organisation (WHO) reported that, as of 22 January, countries including the US, Singapore, Australia, Japan, Thailand and Korea are reporting the presence of this infection. The virus is not currently considered a global health emergency as designated by the WHO but this may change as more data becomes available. The Primerdesign test is therefore well positioned to quickly assist affected countries.Manufacturing site consolidation Following the successful sale of two non-core businesses in 2019, and as part of the strategy to increase profitability, the Company will close its manufacturing facility in Bridport and transfer production to its Camberley site by the end of the first quarter of 2020. In addition to the overhead savings that the consolidation of operations is forecast to deliver, management is confident that this relocation will also deliver additional operating profit to the Group. Following the site consolidation, Novacyt will operate from just two sites in the UK based in Southampton and Camberley.
Outlook for 2020 In 2020, management will continue to focus on increasing gross margins and EBITDA profitability while carefully managing working capital to restore stock levels and deliver sustainable revenue growth. The planned overhead savings will not only improve profitability but extend the Company’s cash runway and enable further investment in rebuilding the supply chain, which is expected to be completed by the middle of 2020. Further cash could be generated in the first half of the year from the sale of the residual NOVAprep® assets, which would provide further working capital. Negotiations are currently underway with various parties to sell the remaining instruments and also some of the residual IP following the successful sale of certain assets to Algimed Trade Ltd in December 2019 for €0.4m plus royalties. Page 3 of 3 Following the successful disposals of the Clinical Lab and NOVAprep® assets and the completion of the financing in 2019, management is focused on driving core business sales growth and profitability in 2020. The year starts with a strong sales order book, new business (VGS Group) and a strong pipeline of new customers for the recently launched PathFlow™ product range in infectious diseases. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. - End –
Niet geheel onbelangrijk, het aantal uitstaande aandelen: Liquidity Agreement Monthly Update and Total Voting Rights Paris, France and Camberley, UK – 3 February 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised in the ‘notes for editors’ section below. During the period from 1 January to 31 January 2020, Invest Securities purchased 76,000 ordinary shares at a maximum price of €0.47 and a minimum price of €0.16 and sold 106,500 ordinary shares at a maximum price of €0.45 and a minimum price of €0.17 under the Liquidity Agreement. The total number of ordinary shares in the Company, which are held in treasury as at close of business on 31 January 2020, is 33,516. Total Voting Rights The total number of ordinary shares in the Company is 59,774,298 following the issue of equity announced on 31 January 2020. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.novacyt.com/wp-content/uploads/2018/0...
Bij griepcontrole voortaan ook check op coronavirus Reizigers in Kuala Lumpur met mondkapjes op. In Maleisië zijn tientallen mensen besmet met het coronavirus. Foto: Reuters Gezondheidsinstituut Nivel breidt samen met het Rijksinstituut voor Volksgezondheid en Milieu (RIVM) de griepsurveillance uit. Ze zullen ook gaan controleren op het coronavirus, om een eventuele uitbraak in Nederland snel te signaleren. Het Nivel brengt sinds 1970 iedere week een schatting van het aantal grieppatiënten uit. Dat doet het instituut op basis van gegevens van veertig huisartsenpraktijken. Het RIVM zal monsters voortaan ook controleren op het coronavirus. Geen gevallen in Nederland Volgens het Nivel is het niet aannemelijk dat het virus wordt aangetroffen. Als dit wel gebeurt, meldt de eigen huisarts dit aan de GGD. Het RIVM en de GGD kunnen dan zo snel mogelijk maatregelen nemen om verdere verspreiding te voorkomen. Er zijn nog geen gevallen van besmetting in Nederland. In China is het coronavirus bij meer dan 40.000 mensen vastgesteld, en zijn er 908 aan overleden. Daarmee is het virus nu dodelijker dan sars in 2002 en 2003.fd.nl/economie-politiek/1334196/griep...
Science News February 11, 2020 / 12:52 PM / Updated 25 minutes ago Novacyt biotech company says winning race for high-speed virus test. PARIS (Reuters) - Franco-British biotech company Novacyt (ALNOV.PA) says it can offer a coronavirus test that is faster than rival methods by focusing on a narrow sequence of DNA coding, as it fights stiff competition to turn the outbreak into a business opportunity. In an appeal for sharing virus samples and speeding up research into drugs, vaccines, and diagnostics, the World Health Organization on Tuesday said China’s coronavirus outbreak posed a “very grave threat for the rest of the world”. To date, China has reported 42,708 confirmed cases, including 1,017 deaths. More than 300 cases are also reported in at least 24 other countries. Novacyt shares have risen by almost 400% so far this year after it said it had designed a test able to detect the coronavirus in less than two hours. Current testing, which can also identify other strains, can take up to a day. The test has not received regulatory approval but Novacyt hopes to receive a green light from the European Union next week and has applied to the United States’ Food and Drug administration for emergency use. It has not disclosed how much it has invested in the test. To assess whether a patient is infected, laboratories screen DNA under a method known as generation sequencing. The samples are large and require lengthy review. Novacyt says it has received orders for 33,000 tests and requests for quotations for another 32,000 from more than 30 countries. Mullis said the tests, to be sold for up to 5 pounds ($6.47) each, would be produced in Britain. Reporting by Matthias Blamont; Editing by Barbara Lewis Our Standards:The Thomson Reuters Trust Principles.
The Chronicle 11 February 2020 Coronavirus ‘a very grave threat’ for world: WHO Coronavirus ‘a very grave threat’ for world: WHO The death toll in the Coronavirus outbreak in China has now reached more than 1 000, after 108 people died from the virus on Monday, the highest daily toll since the outbreak began late last year. The total number of deaths on the mainland was 1 016, the National Health Commission said yesterday. There were 2 478 new confirmed cases, bringing the total to 42 638. In his first public appearance since the outbreak began in the central city of Wuhan, Chinese President Xi Jinping told people in China they “must have confidence” that the country will win its battle against the Coronavirus epidemic. Two deaths have been recorded outside mainland China — one in Hong Kong and one in the Philippines. At least 25 countries have confirmed cases and several nations have evacuated their citizens from Hubei. A second plane carrying 185 Canadian evacuees from Wuhan has landed at an air-force base in Trenton, Ontario, CBC news reported. General Motors’ South Korean unit said that it plans to suspend production at one of its factories on February 17 and 18, becoming the latest automaker affected by a Chinese parts shortage stemming from the coronavirus outbreak in China. The affected line, located in the city of Bupyeong near Seoul, produces the Chevrolet Trailblazer crossover for export to the United States and other markets and domestic sales, she said. Franco-British biotech company Novacyt says it can offer a Coronavirus test that is faster than rival methods by focusing on a narrow sequence of DNA coding, as it fights stiff competition to turn the outbreak into a business opportunity. ----------------------------------------------------------------------------------------------------------------------------------- Novacyt shares have risen by almost 400 percent so far this year after it said it had designed a test able to detect the coronavirus in less than two hours. Current testing, which can also identify other strains, can take up to a day. The test has not received regulatory approval but Novacyt hopes to receive a green light from the European Union next week and has applied to the United States’ Food and Drug Administration for emergency use. ------------------------------------------------------------------------------------------------------------------------------------ Malaysia is crafting a stimulus package for tourism, retail and aviation industries, the Ministry of Economic Affairs said, after a meeting chaired by Prime Minister Mahathir Mohamad. “Today’s meeting discussed specifically the impact of the 2019 novel coronavirus outbreak on the country’s economic growth,” the ministry said in a statement. “Among the sectors identified are the services sectors such as the tourism, retail and aviation industries.” Two Japanese citizens evacuated from Wuhan have been diagnosed with the infection after initially testing negative, the health ministry said. The coronavirus outbreak poses a “very grave threat for the rest of the world”, the head of the World Health Organisation (WHO) said in an appeal for sharing virus samples and accelerating research into drugs and vaccines. “With 99 percent of cases in China, this remains very much an emergency for that country, but one that holds a very grave threat for the rest of the world,” WHO director-general Tedros Adhanom Ghebreyesus said in opening remarks to a meeting of more than 400 researchers and national authorities, including some participating by video conference from mainland China and Taiwan. — AFP Forecast
Hij is binnen. News and Events 14/02/20Posted in Board, Novacyt Group, NOVAPREP®, Products, Services, Uncategorized Update on CE Mark Approved coronavirus test Paris, France and Camberley, UK – 14 February 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that, further to its announcement on 7 February 2020, its subsidiary, Primerdesign Limited, is on schedule to launch a CE-Mark approved nCoV test in the week commencing 17 February
Health News February 14, 2020 / 5:21 PM / Updated 17 hours ago Biotech firm Novacyt to launch coronavirus test next week (Reuters) - Biotechnology company Novacyt said on Friday it would launch a certified test for the coronavirus next week, sending its London-listed shares to a record high. The company said last week that it had applied for U.S. regulatory approval for the test. The flu-like coronavirus outbreak has killed over 1,300 people in China and has continued to spread across the globe, with Chinese health authorities on Friday reporting more than 5,000 new cases. Novacyt’s shares rose 25% to 97 pence as of 1538 GMT on the London Stock Exchange. Kind regards, Forecast
Euronext Company Press Releases:live.euronext.com/listview/company-pr... De meeste zijn eenvoudig via Google Translate te vertalen in het Nederlands.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
Nextensa
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee